Brokerages Set Abivax SA Sponsored ADR (NASDAQ:ABVX) Price Target at $137.15

Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) have earned an average rating of “Moderate Buy” from the fourteen ratings firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, twelve have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $137.1538.

ABVX has been the topic of several recent research reports. Barclays boosted their price objective on shares of Abivax from $142.00 to $148.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 24th. Wall Street Zen cut shares of Abivax from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Guggenheim reaffirmed a “buy” rating and issued a $175.00 price target on shares of Abivax in a report on Thursday, December 18th. Citizens Jmp increased their price target on shares of Abivax from $114.00 to $131.00 and gave the company a “market outperform” rating in a research report on Tuesday, December 16th. Finally, BTIG Research reissued a “buy” rating and set a $150.00 price objective on shares of Abivax in a research note on Wednesday, February 25th.

Institutional Trading of Abivax

A number of large investors have recently made changes to their positions in ABVX. Jefferies Financial Group Inc. purchased a new stake in Abivax in the 3rd quarter valued at about $38,827,000. Kennedy Capital Management LLC lifted its holdings in shares of Abivax by 7.1% during the 2nd quarter. Kennedy Capital Management LLC now owns 241,188 shares of the company’s stock worth $1,845,000 after acquiring an additional 15,997 shares during the period. Federated Hermes Inc. acquired a new stake in shares of Abivax in the third quarter worth approximately $8,448,000. Persistent Asset Partners Ltd acquired a new stake in shares of Abivax in the third quarter worth approximately $815,000. Finally, Atika Capital Management LLC purchased a new stake in Abivax in the third quarter valued at approximately $5,858,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

Abivax Stock Up 3.3%

NASDAQ ABVX opened at $114.97 on Monday. The stock has a market capitalization of $9.10 billion, a P/E ratio of -21.41 and a beta of 1.68. Abivax has a 52-week low of $4.77 and a 52-week high of $148.83. The firm has a 50-day moving average price of $117.82 and a 200 day moving average price of $111.64.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings data on Saturday, February 14th. The company reported ($1.20) earnings per share for the quarter. The business had revenue of $0.52 million during the quarter. On average, equities research analysts expect that Abivax will post -2.83 earnings per share for the current fiscal year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.